Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Compass Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 77 | 78 | +1 |
| Shares | 86.1M | 94.6M | +8.44M (+9.8%) |
| Value | $134.3M | $187.2M | +$52.8M (+39.3%) |
New holders (9)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cormorant Asset Management, LP | 5,560,300 | $11.0M | 0.49% |
| Opaleye Management Inc. | 3,170,000 | $6.28M | 1.37% |
| MPM Oncology Impact Management LP | 1,971,402 | $3.90M | 0.63% |
| Wellington Management Group LLP | 320,621 | $634.8K | 0.00% |
| Simplicity Wealth,LLC | 40,243 | $79.7K | 0.00% |
| Bleakley Financial Group, LLC | 40,243 | $79.7K | 0.00% |
| Algert Global LLC | 16,580 | $32.8K | 0.00% |
| ADAR1 Capital Management, LLC | 10,206 | $20.2K | 0.01% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 16 | $31 | 0.00% |
Sold out (8)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Avidity Partners Management LP | 1,599,600 | $2.50M |
| Ally Bridge Group (NY) LLC | 834,630 | $1.30M |
| Braidwell LP | 317,761 | $495.7K |
| Element Capital Management LLC | 293,888 | $458.5K |
| Susquehanna International Group, LLP | 65,852 | $102.7K |
| Virtu Financial LLC | 28,054 | $44.0K |
| State Board of Administration of Florida Retirement System | 26,320 | $39.0K |
| Wexford Capital LP | 12,700 | $19.8K |